Currently, no definitive diagnostic tool is available to distinguish unifocal and multifocal papillary thyroid carcinoma (PTC). This study aims to identify potential diagnostic markers of multifocal PTC. In 471 Hashimoto's thyroiditis (HT) patients, the significant difference was revealed in anti-thyroid peroxidase antibody (TPOAb) concentration, the cytokeratin-19 (CK-19) expression, the occurrence of the B-Raf proto-oncogene serine/threonine kinase (BRAF) mutations and the rearrangement in transformation (RET)/PTC. The patients' samples were assayed for the expression of CK-19, cyclooxygenase-2 (COX-2), galectin-3, and the protein human bone marrow endothelial cell marker-1 (HBME-1) using immunohistochemistry. The BRAF gene mutation was detected using a sequencer. Differences were examined using the Kruskal-Wallis test and the Chi-squared and Fisher's exact tests. The results showed that the elevated CK-19 expression, and the presence of BRAF mutations and RET/PTC rearrangements were indicators of multifocal PTC in HT, suggesting the need for total bilateral thyroidectomy. Among HT patients with TPOAb > 1300 IU/Ml, the occurrence of central lymph node metastasis is significantly higher in multi-focal PTC than single-focal PTC. Therefore, these markers may prove useful for discerning between uni- and multifocal PTC, thereby preventing unnecessary surgery in the treatment of unifocal PTC and promoting sufficient treatment of multifocal PTC.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6726987 | PMC |
Publication Analysis
Top Keywords
Similar Publications
Aggressive variants of papillary thyroid carcinoma: characteristics, influencing factors, and effectiveness of radioiodine therapy.
J Endocrinol Invest
December 2024
Department of Nuclear Medicine, Zhujiang Hospital of Southern Medical University, Guangzhou, 510220, China.
Purpose: To investigate the pathological characteristics of aggressive variants of papillary thyroid carcinoma (PTC) and evaluate the efficacy of radioiodine (RAI) therapy for these variants.
Methods: We analysed 129 patients with aggressive variants of PTC and compared them to those of 4460 patients with non-aggressive variants. And we examined the efficacy of RAI therapy in 70 eligible patients with aggressive variants of PTC and 2530 eligible patients with non-aggressive variants of PTC.
SIX1 expression and its clinicopathological significance: difference between classic and follicular variant papillary thyroid carcinoma.
Thyroid Res
December 2024
Pathology department, Faculty of Medicine, Minia University, Minia, Egypt.
Article Synopsis
- Papillary thyroid carcinoma (PTC) is the most common type of thyroid cancer, with a generally positive prognosis, but about 10% of patients face mortality due to complications like lymph node metastasis.
- This study aimed to analyze the expression of the SIX1 protein in two PTC subtypes—classic PTC and follicular variant PTC—and its relationship with clinical outcomes.
- Results showed that high SIX1 expression correlated with worse clinical features such as larger tumor size, lymph node metastasis, and other aggressive tumor characteristics, indicating it may serve as a marker for poor prognosis in PTC.
Impact of thyrotropin levels on outcomes in T1N0M0 papillary thyroid cancer after microwave ablation.
Int J Hyperthermia
December 2024
Department of Interventional Medicine, China-Japan Friendship Hospital, Beijing, China.
Article Synopsis
- The study aimed to assess how different levels of thyroid-stimulating hormone (TSH) affect tumor progression and survival in patients with early-stage papillary thyroid cancer treated with microwave ablation (MWA).
- It analyzed the medical records of 525 patients, categorizing them into uni-focal (U-PTC) and multifocal (M-PTC) groups based on TSH levels after treatment, and observed the rates of tumor progression and survival outcomes.
- Results indicated that lower TSH levels in U-PTC patients correlated with higher tumor progression rates and reduced progression-free survival compared to medium and high TSH levels, whereas M-PTC patients showed no significant relationship between TSH levels and progression.
Clinicopathological and molecular characteristics of papillary thyroid carcinoma in adolescent and young adult patients.
Endocr J
December 2024
Department of Tumor and Diagnostic Pathology, Atomic Bomb Disease Institute, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki 852-8523, Japan.
Adolescent and young adult (AYA, 15-39 years old) patients with papillary thyroid carcinoma (PTC) experience significant psychological distress and place great importance on obtaining information regarding the disease; however, their demands remain unmet. We aimed to investigate clinicopathological and molecular features of PTC in AYA patients and compare them to those of PTC in older patients (≥40 years). This retrospective study enrolled 1,677 patients diagnosed with PTC from January 2018 to December 2022, with 400 AYA patients and 1,277 older adults.
View Article and Find Full Text PDFPolygenic Score for Clinicopathologic Features and Survival Outcomes in Papillary Thyroid Carcinoma.
JAMA Otolaryngol Head Neck Surg
November 2024
Department of Head and Neck Surgery, The University of Texas MD Anderson Cancer Center, Houston.
Importance: Genome-wide association studies have identified germline variants associated with the development of papillary thyroid carcinoma (PTC) that can be used to construct a polygenic score (PGS). It is important to determine whether patients with higher germline genetic risk, as summarized using PGS, present with more aggressive disease and/or develop worse clinical outcomes.
Objective: To assess whether germline risk defined by PGS is associated with clinicopathologic features and survival outcomes for patients with PTC.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!